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Abstract
Background: Immunity to malaria develops naturally in endemic regions, but the protective immune mechanisms are
poorly understood. Many vaccination strategies aim to induce T cells against diverse pre-erythrocytic antigens, but
correlates of protection in the field have been limited. The objective of this study was to investigate cell-mediated immune
correlates of protection in natural malaria. Memory T cells reactive against thrombospondin-related adhesive protein (TRAP)
and circumsporozoite (CS) protein, major vaccine candidate antigens, were measured, as were frequencies of CD4
+ CD25
high
T cells, which may suppress immunity, and CD56
+ NK cells and cd T cells, which may be effectors or may modulate
immunity.
Methodology and Principal Findings: 112 healthy volunteers living in rural Kenya were entered in the study. Memory T
cells reactive against TRAP and CS were measured using a cultured IFNc ELISPOT approach, whilst CD4
+ CD25
high T cells,
CD56
+ NK cells, and cd T cells were measured by flow cytometry. We found that T cell responses against TRAP were
established early in life (,5 years) in contrast to CS, and cultured ELISPOT memory T cell responses did not correlate with
ex-vivo IFNc ELISPOT effector responses. Data was examined for associations with risk of clinical malaria for a period of
300 days. Multivariate logistic analysis incorporating age and CS response showed that cultured memory T cell responses
against TRAP were associated with a significantly reduced incidence of malaria (p=0.028). This was not seen for CS
responses. Higher numbers of CD4
+ CD25
high T cells, potentially regulatory T cells, were associated with a significantly
increased risk of clinical malaria (p=0.039).
Conclusions: These data demonstrate a role for central memory T cells in natural malarial immunity and support current
vaccination strategies aimed at inducing durable protective T cell responses against the TRAP antigen. They also suggest
that CD4
+ CD25
high T cells may negatively affect naturally acquired malarial immunity.
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Introduction
Natural immunity that develops against P.falciparum malaria in
endemic regions, providing protection from infection and/or
disease, has yet to be clearly characterised. Acquisition of
immunity against parasitaemia or disease is complicated. The
stages of the parasite life cycle express different antigens against
which the immune system responds with various effector
mechanisms. Studying natural immunity not only improves our
understanding of the pathogen-host interaction but may also
provide clues for the design of malaria vaccines in terms of target
antigens and optimal types of immunity. The role of immune
responses that are not adaptive in nature, such as NK cells, cd T
cells should also be considered, as well as naturally-occurring
CD4
+CD25
high regulatory T cells of unknown specificity. NK cells
and cd T cells may have direct effector functions or may modulate
other immune responses [1,2], whilst naturally-occurring
CD4
+CD25
high FOXP3
+ regulatory T cells may be suppress
immunity [3,4,5]. Different individuals will randomly possess
varying levels of all these cells. T cells against the liver stage of the
malaria life cycle are one way in which sterile immunity may be
effected, by eliminating infected hepatocytes or disrupting parasite
development. This is considered the major mechanism by which
immunisation with irradiated sporozoites elicits sterile protection
in humans [6], as well as mediating the protective effect of various
vaccines in animal models [7]. A number of studies in the field
have implicated T cell responses to the pre-erythrocytic/liver stage
antigen circumsporozoite (CS) protein as being associated with
PLoS ONE | www.plosone.org 1 April 2008 | Volume 3 | Issue 4 | e2027protection against malaria [8,9,10]. Thrombospondin-related
adhesive protein (TRAP) is another pre-erythrocytic antigen that
is a target for T cells and is one of the very few antigens that has
generated protective immunity as a subunit vaccine in humans,
and the only one in which such protection can be clearly attributed
to vaccine-induced T cell responses [11]. Field studies in Africa
have identified CD4
+ and CD8
+ T cell responses to TRAP
induced by natural infection [12], and other studies suggest that
TRAP is under diversifying selective pressure [13] further
supporting a possible role in immune protection.
IFNc-secreting T cells are a major effector mechanism for
elimination of infected hepatocytes [14], together with cytotoxic T
cells [15]. Immediate effector T cell responses can be measured in
an ex-vivo 18 hour IFNc ELISPOT assay, and are thought to
comprise mainly effector-memory T cells which circulate shortly
after antigenic priming or recall [16]. Resting memory T cells
require antigenic re-stimulation and we have utilised an assay to
measure such memory T cells [17], known as the ‘‘cultured IFNc
ELISPOT’’, which reflects a potential IFNc-secreting T cell
capacity within PBMC. We have shown this assay to be capable of
measuring a population of T cells distinct from effector responses
[18], which appear to correlate more closely with protection from
malaria following TRAP vaccination [19].
In this study we aimed to assess cell-mediated immunity as it
relates to immune protection against malarial disease. We have
previously examined ex-vivo T cell responses to TRAP in a cohort
of subjects in a malaria-endemic region of coastal Kenya [20]. The
study showed no relationship between ex-vivo IFNc ELISPOT
response against TRAP peptides, measured before a transmission
season, and reduced malaria incidence in the following year. We
now wished to investigated whether there was a relationship
between resting memory T responses, as measured by cultured
IFNc ELISPOT against TRAP and CS, and subsequent
development of clinical malaria, using stored cells from the same
Kenyan cohort. We assessed how responses against these antigens,
measured in different assays, relate to one another and to subject
age. We also investigated potential correlations of the level of
CD4
+ CD25
high T cells , NK cells, and cd T cells with variable
protection. We found that cultured responses to TRAP but not CS
were significantly associated with reduced malaria, whilst
increased numbers of CD4
+ CD25
high T cells were associated
with increased malaria.
Methods
Subjects, Study Site and Follow up
Healthy volunteers between 1 month and 81 years of age were
recruited from the Kenyan coastal district of Ngerenya. Informed
consent (Consent form Text S2) was obtained from all subjects or
their parent/guardian prior to the donation of 5 mls of venous
blood into heparin anti-coagulant. Blood was taken in the first two
weeks of September 1998, outside of the peak transmission
periods. Ngerenya district is an area of moderate malaria
transmission with an entomological inoculation rate of 10
infectious bites per person per year [21]. Ethical approval for this
study (Ethical approval Text S1) was obtained from the Kenyan
Medical Research Institute National Ethics Committee, as
described previously [20]. Active follow up was performed for
up to one year, with each participant visited weekly. Data for the
entire cohort was analysed for 300 days after the early September
start point. Those reporting subjective fever and/or having a
documented temperature .37.5uC had finger prick blood smears
prepared at Kilifi District Hospital, where parasite densities were
counted. Clinical malaria was defined as a fever and/or
temperature .37.5uC together with .2500 parasites/ml for those
.1 year or ,15 years of age, or any parasitaemia with fever and/
or temperature .37.5uC in those under 1 year of age or
.15 years, as determined in a previous study of this population
[22]. A description of the subject population giving breakdown of
ages represented and malaria incidence during the study are
shown in Table 1. Due to limitations on sample, all tests could not
be carried out on all volunteer samples (Table 2).
T cell responses
Peripheral blood mononuclear cells (PBMCs), separated from
whole blood on a lymphoprep (Axis-Shield, UK) gradient, were
washed and resuspended in RPMI 1640 medium (Sigma, UK)
supplemented 1 in 100 with penicillin/streptomycin, L-glutamine
(Invitrogen, UK) and 10% FCS (Biosera, UK). Cells were set up in
1 ml cultures, in 24-well plates, at 1610
6/ml with peptides at 5–
10 mg/ml, as optimized and described previously [19]. On days 3
and 7, 0.5 ml of culture medium was removed and replaced with
medium containing 100 U/ml IL-2 (Chiron), resulting in a final
Table 1. Descriptive data on age groups tested and malaria
incidence.
Age range
Cultured
TRAP
Cultured
CS FACS
No
malaria
Malaria
episode
0–5 22* 21 28 9 20
5–10 34 26 41 14 30
1 0 – 2 0 2 01 8 2 51 2 1 5
.20 17 14 16 11 7
Total (n) 94 80 112 46 72
*number of individuals in age group per test or according to malaria incidence
doi:10.1371/journal.pone.0002027.t001
Table 2. Association between immune parameters and
incidence of malaria.
Survival (cont.
variable): Univariate Multivariate
Response HR 95% CI p HR 95% CI p n
Cultured TRAP 0.85 0.62–1.20 0.31 0.70 0.47–1.03 0.068 94
Cultured CS 1.07 0.76–1.51 0.69 1.33 0.88–2.032 0.176 80
CD4
+CD25
high 1.55 0.91–2.63 0.11 2.65 0.75–9.36 0.130 108
CD56
dim 0.53 0.25–1.12 0.098 0.35 0.076–1.57 0.17 112
CD56
bright 0.95 0.55–1.65 0.55 1.08 0.32–3.64 0.9 112
cd T cells 1.30 0.42–4.06 0.65 2.5 0.55–11.34 0.24 64
Logistic:
Response OR 95% CI p OR 95% CI p n
Cultured TRAP 0.68 0.41–1.12 0.13 0.50 0.27–0.93 0.028 94
Cultured CS 1.13 0.67–1.89 0.64 1.65 0.83–3.28 0.16 80
CD4
+CD25
high 2.12 0.92–4.91 0.079 2.52 1.05–6.08 0.039 108
CD56
dim 0.27 0.076–1.01 0.076 0.33 0.084–1.29 0.11 112
CD56
bright 0.80 0.33–1.94 0.63 0.70 0.28–1.78 0.46 112
cd T cells 1.39 0.21–9.43 0.74 2.03 0.24–17.03 0.512 64
Univariate and Multivariate analysis with both Cox survival and logistic models
were used to examine the data. HR hazards ratio, OR odds ratio, CI confidence
interval, p,0.05 in bold
doi:10.1371/journal.pone.0002027.t002
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in medium and resuspended in 1 ml, and rested over night, before
proceeding to a IFNc ELISPOT assay. IFNc ELISPOT kits were
purchased from Mabtech (Sweden) and manufacturer’s instruc-
tions followed, with modifications as previously described [19].
Antigenic stimuli used in vitro consisted of a pool of 57 peptides
spanning TRAP and 48 peptides comprising CS (20mers
overlapping by 10aa). Medium-only and PHA controls were used
in all assays. Results are expressed as spot-forming cells (SFCs)/10
6
PBMCs (net antigen-stimulated spots less medium) on day 10
restimulation or ex-vivo.
Intracellular cytokine staining (ICS) and Flow Cytometry
Following the culture period, cell samples were examined for
antigen-stimulated cytokine production by ICS, as previously
optimized for mixed CD4/CD8 T cell responses [23], and
recapitulating the cultured ELISPOT assay. Cells on day 10 were
stimulated with peptides, or were unstimulated, for 20 hours, the
last 18 hours of which were in the presence of 0.1 mg/ml Brefeldin
A. Cells were washed, stained with surface antibodies (CD3, CD4,
CD8) for 20 minutes before further washing and addition of
Perm/Fix for 20 mins. After washing in perm/wash anti-IFNc
antibody was added for 20 minutes, and the cells were washed in
PBS and examined using a FACScalibur. 100,000 cells were
acquired. To examine other cell types in ex-vivo (uncultured)
PBMC, cells were washed and stained for 20 mins with
combinations of the following antibodies: CD56, CD3, CD4,
CD25, cd T cell receptor. For FOXP3 expression intracellular
staining (ebiosciences, USA) as above was preceded by CD4,
CD25 and CD127 staining. Appropriate isotype controls (mouse
IgG2a-FITC, IgG1-PE, IgG1-APC, rat IgG2a-PE-Cy5) were used
in each experiment (Figure S2). 50,000 cells were acquired on the
FACScalibur. Data was analysed using Cellquest and FlowJo
programs. All antibodies, Brefeldin A and ICS kit were purchased
from BD (Oxford, UK).
Statistics
Multivariate analysis was carried out on data using both logistic
and Cox survival models. Survival was additionally analysed using
stratified Kaplan-Meier graphs and the log-rank test. Spearman’s
test was used for correlation. Stata 9 (StataCorp, Texas, USA) was
used for all analysis. The cut-off value for statistical significance
was p,0.05.
Results
Relating cultured IFNc ELISPOT to age, and to ex-vivo
IFNc ELISPOT
The cultured responses of individuals were stratified according
to age into 4 groups: 0–5, 5–10, 10–20, and over 20. TRAP
cultured ELISPOT responses were already high (mean 352 spot-
forming cells (SFC)/M PBMC) in 0–5 year old children, and did
rise further (517 SFC/M) in 5–10 year olds, but not significantly.
In contrast, CS responses were lower in young (0–5 yr) children
(137 SFC/M), and rose significantly with age (10–20 yr; 541 SFC/
M)) (Fig. 1a). For the limited number of ex-vivo responses carried
out, no significant rise was seen for TRAP or CS (Fig. 1b). Dot
plots for these responses are shown in supporting information
(Figure S1). Those individuals for whom sufficient PBMC were
available were tested for cultured and ex-vivo responses against
TRAP (n=23) or CS (n=14), and no correlation between the
responses was observed for either TRAP (p=0.61) or CS
(p=0.76) (data not shown). However, the ex-vivo TRAP and CS
responses did correlate significantly (n=23) (r=0.57,
p=0.0041)(Fig. 2c), and there was a non-significant trend towards
a positive correlation between cultured TRAP and CS responses
(n=70, r=0.21, p=0.08) (Fig. 2d).
Post Culture ICS and Surface Phenotyping
In order to determine the phenotype of T cells responding to
antigens in the cultured ELISPOT assay, ICS was carried out on
day 10 of the culture process. Cultured cells were stimulated with
peptides, or unstimulated, and then stained for surface CD4 and
CD8 and intracellular IFNc. When unstimulated responses (RPMI
only) were compared to peptide-stimulated, a significant increase
was seen for both TRAP (p=0.03) and CS (p=0.004). For TRAP-
responding T cells, 0.47% of lymphocytes that were IFNc
+ were
CD4
+ whilst 0.2% were CD8
+, i.e. a 2.4 fold excess of CD4
+ over
CD8
+ (n=7)(Fig. 3). For CS the fold excess of CD4
+ over CD8
+
was 1.3.
Unstimulated (ex-vivo) PBMC were examined for expression by
lymphocytes of CD4/CD25, CD56 and cd T cell receptor.
Typical plots for CD4/CD25 and CD56 expression are shown
(Fig. 4a,b), demonstrating CD4
+ CD25
high, and CD56
dim/
CD56
bright status. The CD4
+CD25
high populations for a sub-
group of the subjects were examined in more detail using
intracellular staining for FOXP3 (Fig. 4c), where the majority of
FOXP3
+ T cells were CD25
high, and for CD127 surface
expression, where the majority were low/negative (Fig. 4d). Since
Figure 1. Relationship between ELISPOT responses and age.
Cultured ELISPOT responses against (a) TRAP and (b) CS for individuals
were stratified according to age into 4 groups: 0–5, 5–10, 10–20, and
over 20. Median, 25
th and 75
th quartile, 5
th and 95
th quartile and
outlying points are given by box and whisker plots.
doi:10.1371/journal.pone.0002027.g001
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high and FOXP3
+ was seen
(Fig. 4e), CD25
high was used for all further analysis.
Associations with malaria incidence
The initial univariate analyses of the relationship between
immune response and malaria (Table 2), showed a tendancy for
cultured TRAP response (p=0.13) and CD56
dim population
(p=0.076) to be associated with less malaria, and for CD4
+
CD25
high cells with increased malaria (p=0.079). A similar
pattern was seen for logistic and Cox survival analyses. When a
multivariate model was applied, adjusting for age and including
both cultured CS and TRAP responses, the association between
TRAP responses and protection became stronger (p=0.068 for
Cox survival, p=0.028 for logistic regression), whilst multivariate
analysis showed a significant association between increased CD4
+
CD25
high population and increased malaria risk (p=0.039).
The adjusted survival functions of level of cultured ELISPOT
response to TRAP or CS is shown for individuals stratified into
three tertiles according to response, as Kaplan-Meier graphs
(Fig. 5). When analysed by tertile, a similar pattern was seen to the
previous analysis, with a significant association with reduced
malaria observed for cultured ELISPOT response to TRAP
(Fig. 5a)(p=0.046), in contrast to CS (Fig. 5b)(p=0.20).
Multivariate analysis of the possession CD4
+CD25
high T cells
showed a significant association with increased malaria incidence
(p=0.039). Since CD4
+CD25
high cells are known to have
inhibitory effects on T cell responses, including proliferation, this
population was compared to cultured ELISPOT responses by
regression analysis. No negative or positive association between
their frequency and cultured ELISPOT responses to TRAP
(p=0.9) or CS (p=0.62) was observed (data not shown). No
significant associations with survival were observed for the
numbers of cd T cells.
Discussion
The search for immune responses and parameters that may
contribute to natural immunity and influence the incidence of
Figure 2. Correlations between ELISPOT responses. The relationship was examined between (a) TRAP and CS responses both ex-vivo, and (b)
TRAP and CS responses both cultured.
doi:10.1371/journal.pone.0002027.g002
Figure 3. Intracellular IFNc Staining following culture. ICS for IFNc was carried out on cells by restimulation with peptides, following 10 days
of culture, and co-staining with CD4 or CD8. The mean percentages (6standard deviation) of IFNc
+ cells possessing CD4 or CD8 (with medium
controls subtracted) are shown together with the mean CD4:CD8 ratio.
doi:10.1371/journal.pone.0002027.g003
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obtaining blood samples from carefully monitored individuals,
particularly of young age, in regions where malaria is endemic.
Our initial study on this cohort of individuals measured ex-vivo T
cell responses against selected TRAP peptides and showed no
association between responses and protection [20]. Previous data
suggests that ex-vivo and cultured ELISPOT assays measure
distinct populations of responder T cells [18,19], possibly due to
differing priming and homeostatic mechanisms. Further, it
appeared that cultured responses may associate better with
protection from malaria both in malaria-naı ¨ve individuals
following TRAP vaccination in the UK [19] and in studies of
responses to the CS protein in The Gambia [9]. This study
therefore aimed to investigate whether naturally-acquired memory
T cell responses to TRAP or CS, as measured by cultured
ELISPOT, and other cell-mediated immune parameters, are
associated with malaria incidence in the field.
Stratification of responses by age was carried out to determine
whether immune response, as resistance to infection or disease, is
simply acquired over time. TRAP cultured responses were
established early, during the first 5 years of life, and did not
significantly increase thereafter. In contrast, responses to CS
developed more slowly with a significant rise over time. The ex-vivo
responses showed a similar pattern of development of response
over time, although the number of individuals examined
.20 years were few. These data suggest that TRAP may be a
more immunogenic antigen for T cell responses than CS since
responses to it are generated more rapidly. Indeed, this is
consistent with the weaker immunogenicity observed for CS
compared to TRAP when DNA and viral vector vaccines were
used in prime-boost regimens both in the UK [24,25] and in the
field [26,27].
A comparison of antigen-specific responses showed that ex-vivo
TRAP and CS responses correlated significantly, suggesting recent
simultaneous exposure to these antigens in responding individuals.
However, ex-vivo responses did not correlate with cultured
responses to the same antigen, either for TRAP or CS, confirming
our earlier findings [18]. There was a trend for cultured TRAP
and CS responses to correlate, perhaps reflecting their differences
in intrinsic immunogenicity but suggesting simultaneous exposure.
Investigation of the phenotype of responding cells by ICS revealed
a predominance of CD4
+ IFNc
+ cells against TRAP, again similar
to our previous findings [12,23], compared to a more balanced
CD4
+/CD8
+ composition for responses to CS.
In order to examine the relationship between immune
parameters and malaria incidence, analysis models used survival
as a continuous variable or logistically, and included age and all
responses as co-variates in multivariate analysis (Table 2). Age is
particularly important as resistance (‘‘protective immunity’’) to
disease and infection develops over time, potentially mediated by
numerous factors in addition to cell-mediated immunity.
Throughout all the analyses the phenotypes consistently associated
Figure 4. Characterisation of regulatory T cells and NK cells. Ex-vivo PBMC were stained for surface CD4, CD25 and CD127, and intracellularly
for FoxP3. Typical dot plots show (a) the distribution of CD25 determining CD25
high status, (b) the distribution of CD56 on CD3 negative (NK) cells
determining CD56
dim and CD56
bright status, (c) that the majority of FoxP3
+ cells are CD25
high, and (d) that the FoxP3
+ cells are predominantly CD127
2
[28]. (e) A correlation was demonstrated between CD25
high and FoxP3 positivity.
doi:10.1371/journal.pone.0002027.g004
Protective T Cells to TRAP
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and the CD4
+CD25
high population, but there was also weaker
evidence of some association with the CD56
dim population and
reduced incidence. The cultured TRAP response was significantly
associated with reduced malaria incidence. Depletion studies have
demonstrated that the responding cells in cultured IFNc ELI-
SPOT possess the central memory T cell marker CCR7 prior to
culture [17], [S Todryk unpublished]. Therefore, this suggests that
the possession of such memory T cells against TRAP provides a
protective advantage against malaria which would be generated by
multiple contacts with antigen and remain at detectable levels once
antigen levels have dropped, while the effector T cell numbers
decline. These memory T cells become activated to proliferate and
differentiate into effector cells upon re-exposure to antigen during
a subsequent liver stage infection. Thus, a population of IFNc-
secreting T cells are provided that are capable of interfering with
the liver stage of the life cycle, thus reducing or preventing
merozoite release. The fact that the relationship between these
cultured TRAP responses and malaria incidence is only moder-
ately significant may not be surprising as many other factors are
likely to contribute to protection in the field. These could include
T cells reactive to other liver-stage antigens (although not CS, as
shown in this study), antibody responses and innate mechanisms,
and immunity to other stages of the life-cycle. Interestingly, the
level of TRAP cultured ELISPOT response associated with
protection here is in the range currently achievable by vectored
vaccination regimes, at least in UK vaccinees, of around 400
SFC/M [19]. There was a difference between these findings and
our recent studies (in conjunction with a vaccine trial [26]) in a
neighbouring region of Kenya, where responses in non-vaccinated
children were lower and not associated with protection. This may
be due to reduced overall incidence in malaria in 2005 compared
to 1998, as well as the locational difference, giving rise to less less T
cell priming and not posing as testing a challenge as in 2005.
We found some weak evidence that increased CD56
dim
populations may be associated with reduced malaria incidence.
CD56
dim NK cells are known to be cytolytic [1] and so may have
activity against host cells harbouring parasites and expressing
parasite antigens or stress molecules.
Lastly, individuals with higher numbers of CD4
+CD25
high T
cells were significantly associated with increased susceptibility to
malaria. Cells of this phenotype will vary randomly within any
human population dependant on a variety of extrinsic and
intrinsic factors. The T cells are usually considered regulatory T
cells when they express high levels of FOXP3. Such cells are
known to inhibit proliferation of T cells in an antigen non-specific
manner and may therefore inhibit parasite-specific T cells, as has
been demonstrated in mouse [4] and human [5] malaria challenge
models. In view of the many potential immune responses that
could be affected by this CD4
+CD25
high cell population, further
Figure 5. Kaplan-Meier malaria-free survival plots. Individuals were stratified into low, medium and high cultured ELISPOT responders (SFC/
10
6) to (a) TRAP and (b) CS and probability of remaining free of clinical malaria is plotted over the 300 day monitoring period. Co-variants
incorporated into the analysis are age and antigen response to the other antigen.
doi:10.1371/journal.pone.0002027.g005
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warranted. We found no negative correlation between levels of
these cells and levels of cultured ELISPOT reactivity against
TRAP or CS suggesting an absence of inhibitory effects on these T
cell responses, at least in vitro. The CD25
high T cells could be
affecting other T cell specificities, or other arms of the immune
response.
Overall, these findings support a role of cell-mediated immunity
in resistance to malaria infection, in particular T cell memory
against TRAP. They also highlight the probability that both
multiple adaptive and innate mechanisms together contribute to
an individual’s susceptibility to infection and/or disease. This
complex relationship warrants further investigation in larger
studies if we are to further dissect the mechanisms of natural
protective immunity.
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